SUPPLEMENTAL INFORMATION (Tables)

3 Months Ended

Mar. 31, 2024

Geographic Areas, Long-Lived Assets [Abstract]

Schedule of long-lived assets by location

The following table presents long-lived assets by location:

	March 31, 2024		December 31, 2023
	Unaudited		Audited
United States	$	45,358	$	41,634
Israel	8,290		8,317
Switzerland	10,940		7,733
Others	6,240		5,179
Total long lived assets	$	70,828	$	62,863

Schedule of Revenues by Geographic Region

The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:

	Three months ended March 31,				Year ended December 31,
	2024		2023		2023
United States	$	90,543	$	85,228	$	349,743
International markets:
Germany	15,747		15,120		60,210
Japan	7,817		8,669		31,668
Other international markets	19,459		7,850		44,493
International markets - Total	43,023		31,639		136,371
Greater China (1)	4,937		5,315		23,224
Total net revenues	$	138,503	$	122,182	$	509,338

(1) For additional information, see Notes 12 and 13 to the Consolidated Financial Statements in the 2023 10-K.

Schedule of Restructuring and Related Costs

	Three months ended March 31,		Year ended December 31, 2023
	2024
	Unaudited		Audited
Cost of revenues	$	52	$	262
Research, development and clinical studies	275		2,070
Sales and marketing	1,539		2,404
General and administrative	164		1,495
Total restructuring cost	$	2,031	$	6,231
Restructuring costs paid during the period	$	5,128	$	2,753